Dcvc Opportunity Fund Ii Gp, LLC Recursion Pharmaceuticals, Inc. Transaction History
Dcvc Opportunity Fund Ii Gp, LLC
- $97.2 Million
- Q3 2024
A detailed history of Dcvc Opportunity Fund Ii Gp, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Dcvc Opportunity Fund Ii Gp, LLC holds 3,951,141 shares of RXRX stock, worth $28.6 Million. This represents 26.78% of its overall portfolio holdings.
Number of Shares
3,951,141
Previous 3,951,141
-0.0%
Holding current value
$28.6 Million
Previous $29.6 Million
12.13%
% of portfolio
26.78%
Previous 44.96%
Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$237 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$183 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$176 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$125 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$111 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.31B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...